News stories about Vertex Pharmaceuticals (NASDAQ:VRTX) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Vertex Pharmaceuticals earned a daily sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the pharmaceutical company an impact score of 45.7720911053064 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Here are some of the news articles that may have effected Accern Sentiment Analysis’s rankings:

Vertex Pharmaceuticals (VRTX) traded up $1.93 during midday trading on Wednesday, hitting $147.04. 897,411 shares of the stock traded hands, compared to its average volume of 1,809,584. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. Vertex Pharmaceuticals has a twelve month low of $71.46 and a twelve month high of $167.85. The stock has a market capitalization of $36,579.86, a price-to-earnings ratio of 241.07, a price-to-earnings-growth ratio of 3.67 and a beta of 1.63.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.04 by $0.49. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The business had revenue of $578.20 million during the quarter, compared to analyst estimates of $522.07 million. During the same quarter last year, the firm posted $0.16 earnings per share. The business’s revenue for the quarter was up 39.7% compared to the same quarter last year. analysts forecast that Vertex Pharmaceuticals will post 0.72 EPS for the current fiscal year.

A number of equities analysts have weighed in on the stock. TheStreet cut shares of Vertex Pharmaceuticals from a “b-” rating to a “c+” rating in a research report on Wednesday, July 26th. Needham & Company LLC restated a “buy” rating and set a $195.00 price objective on shares of Vertex Pharmaceuticals in a research report on Friday, October 27th. BMO Capital Markets restated an “outperform” rating and set a $182.00 price objective (up from $180.00) on shares of Vertex Pharmaceuticals in a research report on Thursday, July 27th. Vetr cut shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 price objective for the company. in a research report on Monday, September 4th. Finally, BidaskClub cut shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-three have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $173.15.

TRADEMARK VIOLATION NOTICE: This article was first posted by Daily Political and is the property of of Daily Political. If you are accessing this article on another site, it was illegally copied and reposted in violation of United States and international copyright legislation. The legal version of this article can be read at https://www.dailypolitical.com/2017/11/22/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-vertex-pharmaceuticals-vrtx-stock-price.html.

In related news, EVP David Altshuler sold 1,796 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $160.00, for a total value of $287,360.00. Following the sale, the executive vice president now owns 107,807 shares of the company’s stock, valued at $17,249,120. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CMO Jeffrey Chodakewitz sold 3,437 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $151.64, for a total transaction of $521,186.68. The disclosure for this sale can be found here. In the last three months, insiders sold 220,315 shares of company stock valued at $32,107,270. Insiders own 1.80% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.